-
Blood | Using iPS cells in vitro hematopoietic cell differentiation system to study hereditary aplastic anemia caused by gene defects related to formaldehyde metabolism
Time of Update: 2021-05-22
The mutation of ALDH2 (Aldehyde Dehydrogenase 2, acetaldehyde dehydrogenase 2) and ADH5 (Alcohol Dehydrogenase 5, alcohol dehydrogenase 5) causes the formaldehyde produced in the process of hematopoietic differentiation cannot be decomposed normally, DNA damage is accumulated, and then induced Aplastic anemia occurs and eventually develops into leukemia.
-
Key points of the updated CSCO guidelines for diagnosis and treatment of hematological malignancies
Time of Update: 2021-05-22
From April 23rd to 24th, the 2021 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was successfully held. At the meeting, Professor Gong Tiejun from the Harbin Institute of Hematolo
-
Flash report: FDA approves single injection therapy using carboxymaltose iron injection
Time of Update: 2021-05-21
S. Food and Drug Administration (FDA) approved a single injection of 1000 mg of iron carboxymaltose to treat adult patients with iron deficiency anemia.
Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia.
-
NEJM: How effective is the Pfizer vaccine against the B.1.1.7 and B.1.351 variants of the new coronavirus?
Time of Update: 2021-05-21
5%Recently, a study published on NEJM showed that the effectiveness of Pfizer vaccine against any B.
1. 351 variants in the country, the Pfizer vaccine is effective against infections and diseases in the Qatari population.
-
Urgent clinical need!
Time of Update: 2021-05-21
In April 2018, the FDA approved the marketing of brozoyuumab for the treatment of X-linked hypophosphatemia in children and adults 1 year and older.
Retrieved May 11, 2021, from 2] Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita®(burosumab-twza) for the Treatment of Children and Adults with X--Linked Hypophosphatemia (XLH).
-
JCO: Efficacy and safety of ixazomib+darelimumab+dexamethasone in frail patients with multiple myeloma
Time of Update: 2021-05-21
6 months and 92%, respectively, and the median PFS and 12-month OS of patients 80 years and younger based on other frailty parameters They were 13.
The median PFS and 12-month OS of frail patients> 80 years old based on other frailty parameters were 10.
-
PBJ | New advances in lettuce chloroplast transformation: the use of plant cell-expressed proteins for early intervention and treatment of hemophilia B
Time of Update: 2021-05-21
Therefore, expressing the coagulation factor FIX in plants and fusing with appropriate transporters to release them in appropriate organs and timing is a potential solution for the treatment of hemophilia B.
-
Lancet oncol: Loncastuximab tesirine can effectively treat relapsed/refractory DLBCL!
Time of Update: 2021-05-21
1016/S1470-2045(21)00139-X" target="_blank" rel="noopener">Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial .
1016/S1470-2045(21)00139-X" target="_blank" rel="noopener">Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial in this message
-
PNAS: Scientists have designed new drug compounds to curb malaria
Time of Update: 2021-05-21
Recently , in a study published in PNAS , scientists have developed a set of compounds that can directly inhibit the activity of SUB1 to prevent parasites from erupting from red blood cells and from proliferating.
-
Caplacizumab can prevent death and refractory conditions in acquired thrombotic thrombocytopenic purpura: comprehensive analysis results
Time of Update: 2021-05-21
Research Results and Discussion This comprehensive analysis of 220 participants in the TITAN and HERCULES studies (108 in the caplacizumab group; 112 in the placebo group) provides information on the benefits of caplacizumab in reducing mortality and refractory diseases in patients with aTTP New evidence of incidence and no new safety issues.
-
Case challenge: Main complaint-Progressive dysphagia for 1 year, exacerbated by 3 months
Time of Update: 2021-05-21
5 Blood pressure: 90 58 mmHg Gender: Female age: 40 Heart rate: 66 Respiration rate: 19 Pulse: 66 Main complaint: Progressive dysphagia for 1 year, worsening for 3 months History of present illness: One year ago, there was no obvious cause of dysphagia, and it was obvious when eating solid food, accompanied by nausea and vomiting.
-
Stem Cell Research & Therapy: miR-424-5p can be used as a biomarker for early heart disease
Time of Update: 2021-05-21
A study published in the " stem cell research and treatment " ( Stem the Cell Research, ) study showed that , in patients with type 1 diabetes often give the diagnosis may have characteristics of premature heart disease induced by the disorder before.
-
NEUROBIOL AGING: Obesity is related to decreased cerebral blood flow
Time of Update: 2021-05-21
008Scientists from the Longitudinal Study on Aging in Ireland (TILDA) investigated the body mass index (BMI), waist-to-hip ratio and waist circumference, physical activity of adults over 50 and found that being overweight or obese significantly reduces cerebral blood flow.
-
Aging Cell: How do aging immune cells change in the elderly?
Time of Update: 2021-05-20
infectionRecently, researchers used the second-generation β-galactosidase fluorescent substrate and multi-parameter flow cytometry to prove that peripheral blood mononuclear cells (PBMCs) isolated from healthy people as the donor ages Shows a high degree of aging-related β-galactosidase (SA-βGal) activity.
-
Nat Commun: Using clinical transcriptome methods to stratify and treat patients with acute myeloid leukemia
Time of Update: 2021-05-20
The researchers further showed that these patients may benefit from the treatment of focal adhesion kinase inhibitors encoded by PTK2 , indicating that transcriptome-based tests have additional utility in the treatment of myeloid malignancies.
-
Radiology: Prognostic value of IVIM sequence in newly diagnosed AML
Time of Update: 2021-05-20
Recently, a study published in the journal Radiology explored whether bone marrow IVIM parameters can predict the overall survival (OS) of newly diagnosed AML patients, providing a valuable reference for early clinical, accurate and non-invasive assessment of the prognosis of AML patients.
-
Br J Cancer: Study on the correlation between the number of siblings and the survival rate of children with leukemia
Time of Update: 2021-05-20
Acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) are the two most common leukemias, with 5-year survival rates of 88% and 64%, respectively.
AML patients with siblings also showed a trend of higher survival rates, with disease risk ratios of 0.
-
Stroke: The relationship between cerebral hemodynamics and executive function in patients with sickle cell anemia
Time of Update: 2021-05-20
do?w=%E5%BF%83%E8%A1%80%E7%AE%A1">heart blood vessels published a research article on the disease areas prestigious journal Stroke, the study aims to test the following hypothesis: sickle cell anemia in patients with cerebral blood flow and oxygen extraction fraction increases associated with lower executive function.
-
Nursing safety is no small matter!
Time of Update: 2021-05-10
Upon review, the court of second instance of the original trial held that: "When the appellant claimed that his relatives were seeking medical treatment at the appellee's place, the appellee failed to fulfill his guardianship duties, causing the patient to fall and died after the rescue was invalid.
-
CPX-351 can significantly prolong OS in newly diagnosed high-risk/secondary elderly AML patients: post-mortem analysis of phase 3 study
Time of Update: 2021-05-10
The preliminary results of a key, randomized phase 3 study of newly diagnosed high-risk/secondary elderly AML patients showed that CPX-351 was used for consolidation therapy after induction therapy, and the median overall survival (OS [primary endpoint]; 9.
